Background: Tazarotene is a new 3rd generation topical acetylenic retinoid. It normalizes keratinocyte differentiation, reduces keratinocyte proliferation and decreases expression of inflammatory markers. Tazarotene was approved by US FDA in 1997 for acne vulgaris. Objectives: To evaluate the efficacy and safety of topical tazarotene 0.1% cream in the treatment of facial acne. Materials and methods: 67 patients with facial acne in the age range of 13-30 years were enrolled in the study.